Empire Life Investments Inc. lowered its position in Becton Dickinson and Co (NYSE:BDX) by 9.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,097 shares of the medical instruments supplier’s stock after selling 7,719 shares during the quarter. Becton Dickinson and makes up about 1.5% of Empire Life Investments Inc.’s portfolio, making the stock its 29th biggest position. Empire Life Investments Inc.’s holdings in Becton Dickinson and were worth $16,696,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in BDX. IMS Capital Management bought a new stake in Becton Dickinson and during the 3rd quarter valued at $29,000. JCIC Asset Management Inc. bought a new stake in Becton Dickinson and during the 4th quarter valued at $54,000. Signet Investment Advisory Group Inc. bought a new stake in Becton Dickinson and during the 4th quarter valued at $56,000. Patriot Financial Group Insurance Agency LLC boosted its position in Becton Dickinson and by 87.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 273 shares of the medical instruments supplier’s stock valued at $62,000 after acquiring an additional 127 shares in the last quarter. Finally, Essex Savings Bank bought a new stake in Becton Dickinson and during the 4th quarter valued at $67,000. 86.28% of the stock is currently owned by institutional investors.
BDX has been the topic of several recent research reports. Morgan Stanley dropped their target price on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 2nd. Barclays initiated coverage on Becton Dickinson and in a research report on Monday, October 15th. They set an “equal weight” rating and a $278.00 target price on the stock. TheStreet cut Becton Dickinson and from a “b+” rating to a “c+” rating in a research report on Friday, December 7th. UBS Group initiated coverage on Becton Dickinson and in a research report on Tuesday, November 27th. They set a “neutral” rating and a $260.00 target price on the stock. Finally, KeyCorp increased their target price on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a research report on Thursday, November 8th. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Becton Dickinson and has an average rating of “Buy” and a consensus price target of $253.17.
Becton Dickinson and stock opened at $242.78 on Tuesday. The company has a quick ratio of 0.62, a current ratio of 0.97 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $65.45 billion, a PE ratio of 22.05, a price-to-earnings-growth ratio of 1.70 and a beta of 1.23. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.58 by $0.12. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The business’s quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.48 EPS. As a group, equities research analysts expect that Becton Dickinson and Co will post 12.1 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be given a $0.77 dividend. The ex-dividend date of this dividend is Thursday, March 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.27%. Becton Dickinson and’s payout ratio is 27.97%.
In related news, insider Thomas E. Polen, Jr. sold 5,243 shares of the firm’s stock in a transaction on Monday, November 19th. The stock was sold at an average price of $243.86, for a total value of $1,278,557.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James W. Borzi sold 5,887 shares of the firm’s stock in a transaction on Friday, November 30th. The stock was sold at an average price of $252.37, for a total value of $1,485,702.19. Following the completion of the transaction, the executive vice president now owns 6,013 shares of the company’s stock, valued at approximately $1,517,500.81. The disclosure for this sale can be found here. Insiders sold a total of 17,740 shares of company stock valued at $4,349,242 in the last three months. Insiders own 0.12% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2019/02/12/becton-dickinson-and-co-bdx-shares-sold-by-empire-life-investments-inc.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: Why Dividend Stocks May Be Right for You
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.